Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis - PubMed
8 days ago
- #multiple sclerosis
- #high-efficacy therapy
- #disability progression
- Study assesses the real-life effectiveness of high-efficacy therapies (HET) versus moderate efficacy therapies (MET) on progression independent of relapse and MRI activity (PIRMA) in relapsing-onset MS (RMS) patients.
- Data from 10,499 RMS patients in the French MS Registry (2010-2023) with a mean follow-up of 3.7 years were analyzed.
- Primary outcome: Time-to-first PIRMA was slightly shorter in the HET group (8.7 years) vs. MET group (8.9 years).
- Secondary outcomes: Time-to-first confirmed disability progression (CDP) tended to be longer in the HET group (7.6 years) vs. MET group (7.3 years).
- Relapse-associated worsening (RAW) and MRI-associated worsening (MAW) occurred earlier in the MET group compared to HET.
- Baseline risk factors for increased PIRMA incidence included high EDSS, older age, and spinal cord lesions.
- Conclusion: HET better controls disability accumulation related to disease activity, but PIRMA-related mechanisms are not differentially affected by HET vs. MET.